National Health and Medical Research Council Act 1992

Researchers and research institutions. Universities, research hospitals, and individual researchers who apply for NHMRC grants are directly affected. All recipients of funding from the Medical Research Endowment Account must agree to comply with the human research guidelines (section 51(3)). NHMRC guidelines on research ethics effectively set the minimum standards for all publicly funded medical research in Australia.

Clinicians and health practitioners. Clinical practice guidelines issued by the CEO under section 7(1)(a) address diagnosis, treatment, disease prevention, and health care provision. While the guidelines are not legislative instruments (section 9(3)) and do not have direct legal force, they are widely adopted as professional standards and routinely cited in negligence litigation and regulatory proceedings.

State and territory health authorities. The Council includes all state and territory chief medical officers (section 20(2)(c)). NHMRC guidelines are also addressed to state and territory governments (section 7(1)(b)), making the body a central mechanism for national consistency in health standards.

Businesses providing health products or services. ACCC proceedings have relied on NHMRC guidelines as evidence of the scientific consensus against which health-related advertising claims are assessed. Businesses making health representations that contradict NHMRC guidelines risk misleading and deceptive conduct proceedings under the Australian Consumer Law.

Grant applicants and complainants. A person whose interests are affected by a "reviewable action" (which covers grant-making and related CEO decisions) may complain to the Commissioner of Complaints under Part 8 on procedural grounds.

Public consultation. Before the Council can provide a regulatory recommendation to the CEO, it must publish a notice of intention on the NHMRC website inviting submissions, then publish a draft recommendation inviting further submissions, and have regard to all submissions received (section 12). For guidelines (other than human research guidelines), the Council must prepare a draft, publish it for comment, and have regard to submissions (section 13). For human research guidelines, the Australian Health Ethics Committee follows an equivalent process (section 13). These obligations may be bypassed only in urgent circumstances or for matters of minor significance (sections 14 and 14B).

Tabling in Parliament. Human research guidelines must be tabled in each House within 15 sitting days of issue (section 10(4)). If the Minister gives a direction to the CEO, Council or a Principal Committee, the Minister must table a statement of the direction and its reasons within 15 sitting days (section 5E(4)).

CEO must publish research timetables. Each financial year, the CEO must publish a timetable and procedures for making grant recommendations from the Account (section 8(1)).

Notification of complaint investigations. Before the Commissioner begins investigating a complaint, the CEO must be informed (section 62).

Co-operation with Commissioner. Persons covered by the investigation (CEO, delegate, Research Committee and relevant staff) must co-operate with the Commissioner and provide requested information and documents (section 64).

Recipients' ethics compliance. Funding recipients from the Account must agree to comply with the NHMRC's human research guidelines (section 51(3)).

Ministerial directions. The Minister may direct the CEO, Council or a Principal Committee in writing as to the performance of their functions (section 5E(1)). Directions must be of a general nature only; the Minister cannot direct specific funding outcomes or how to treat scientific, technical or ethical issues (section 5E(2)). The CEO, Council or Committee must comply with valid directions (section 5E(3)).

Ministerial referrals. The Minister may refer any matter within the scope of the CEO's, Council's or a Principal Committee's functions to be dealt with (section 5D(1)), and the body must deal with the referral.

CEO's power to act urgently. If a matter must be dealt with urgently, the CEO may make an interim regulatory recommendation or issue interim guidelines without having received them from the Council (section 14(1)). Within 30 days, the CEO must publish reasons and invite public submissions (section 14(2)).

Commissioner's discretion not to investigate. The Commissioner may decline to investigate or discontinue investigation if the complaint is more than 12 months old, frivolous, vexatious, not made in good faith, or not otherwise justified (section 61(1)). The Commissioner may transfer privacy-related complaints to the Information Commissioner under the Privacy Act 1988 (section 61(4)-(6)).

Confidential commercial information. The CEO may disclose confidential commercial information obtained by NHMRC officers to a person if the Minister certifies public interest necessity, if regulations specify the recipient, or if the information provider has authorised disclosure (section 80(5)).

Section 80(2): Disclosure of confidential commercial information. An NHMRC officer who discloses confidential commercial information acquired in their capacity as an NHMRC officer commits an offence, punishable by imprisonment for 2 years. The penalty applies whether the information was acquired by the CEO, a Council or committee member, staff, a consultant, or persons assisting the Commissioner.

Section 80(7): Disclosure without notification. If the CEO or Commissioner discloses information under the authorised-by-information-provider pathway (sections 80(5)(c) or 80(6)(c)) without first notifying the information provider and giving them a reasonable opportunity to comment, the same 2-year imprisonment penalty applies.

No broader civil penalty regime exists under the Act. Procedural complaints are handled by the Commissioner of Complaints, whose power is to report and recommend rather than to make binding orders.

Guideline development process:

1. Council decides to develop a regulatory recommendation and publishes a notice on the NHMRC website inviting submissions (section 12(2)).
2. After submissions close, Council publishes a draft recommendation inviting further submissions (section 12(3)(a)).
3. Council has regard to submissions and provides the finalised recommendation to the CEO (section 12(4)).
4. CEO issues the recommendation, which must be in precisely the form provided by the Council (section 9(1)).

Urgent recommendations: If urgency applies, the Council may provide a recommendation without full consultation (section 14(3)). Within 30 days of the CEO issuing an urgent recommendation, the Council must publish reasons and invite submissions on the issued text (section 14(4)).

Complaint timeline: A complaint must be made within 12 months of the complainant becoming aware of the reviewable action (section 61(1)(c)). Before making a complaint to the Commissioner, the complainant should approach the CEO directly unless that would be unreasonable (section 61(1)(e)). The Commissioner investigates in private (section 63).

Ministerial directions tabling: Within 15 sitting days of giving a direction under section 5E, the Minister must table a statement of particulars and reasons in each House (section 5E(4)).

Research Involving Human Embryos Act 2002: The Embryo Research Licensing Committee of the NHMRC is established under that Act (section 13) as a Principal Committee of the NHMRC. However, the NHMRC Act expressly carves it out of various provisions: the Minister cannot refer matters to it under section 5D, it is outside the Commissioner's complaint jurisdiction, and it is not counted among the committees whose members are officials of the NHMRC for PGPA purposes beyond subsection 5B(2)(b).

Public Governance, Performance and Accountability Act 2013: The NHMRC is a listed entity, the CEO is the accountable authority, and the Act incorporates PGPA finance law obligations throughout (section 5B(3)).

Privacy Act 1988: The Commissioner may transfer complaints to the Information Commissioner if a complaint could be more conveniently or effectively dealt with under Part V of the Privacy Act (section 61(4)-(6)).

Australian Consumer Law / Competition and Consumer Act 2010: NHMRC guidelines issued under section 7(1)(a) are treated as evidence of established scientific consensus in ACCC enforcement proceedings. In ACCC v Homeopathy Plus Australia [2014] FCA 1412, the court considered NHMRC guidelines as part of the evidentiary framework for assessing whether health-related representations were misleading.

Therapeutic Goods Act 1989: NHMRC health guidelines intersect with TGA regulation of medicines and vaccines. In practice, NHMRC vaccination guidelines are developed in parallel with TGA product approvals, and ACCC proceedings have referred to both frameworks when assessing claims about vaccine safety and efficacy.

Guidelines are not legislative instruments and do not have direct legal force. Section 9(3) expressly provides that regulatory recommendations and guidelines are not legislative instruments. They do not bind practitioners, hospitals or individuals as a matter of law. However, in professional negligence proceedings, departure from NHMRC guidelines can be relevant to the standard of care. And in ACCC proceedings, making representations that contradict NHMRC guidelines is strong evidence of misleading conduct.

The CEO cannot deviate from the Council's text. The Act is unusually strict: under section 9(1), the CEO can only issue a recommendation or guideline "precisely as developed by the Council... and provided to the CEO by the Council." The CEO has discretion about whether to issue it at all, but not about the content. This is a safeguard against political interference in scientific standards.

The Commissioner cannot review funding merits. Section 56(2) is explicit: the Commissioner must not enquire into the merits of a recommendation or decision by the CEO, a delegate, or the Research Committee in the course of a reviewable action. Disappointed grant applicants who believe a better scientific case was overlooked cannot use the Commissioner to relitigate the funding decision. The Commissioner's role is limited to procedural fairness and administrative law grounds listed in section 58.

The 12-month complaint window. Under section 61(1)(c), the Commissioner may decline to investigate if the complainant became aware of the matter more than 12 months before complaining. Applicants who do not promptly identify and escalate process failures risk losing the right to complain.

Human research guidelines bind funding recipients. It is a mandatory condition of all funding from the Medical Research Endowment Account that recipients agree to comply with the human research guidelines (section 51(3)). Researchers who breach ethics guidelines risk losing funding eligibility and may trigger Commonwealth recovery action.

Confidential commercial information can flow to courts. Section 80(4) provides that the NHMRC secrecy obligation does not preclude disclosure of confidential commercial information in court proceedings, but the court must prevent wider disclosure. Businesses that provide commercially sensitive information to the NHMRC to support guideline development do not receive absolute protection from court disclosure.

Example 1: Developing clinical practice guidelines. A medical professional body approaches the NHMRC requesting updated guidelines on managing a chronic condition. The Research Committee advises the Council on the research base. The Council directs that a guideline development process commence, publishes a notice inviting public submissions, then publishes a draft guideline for further comment. After reviewing submissions, the Council provides the finalised guideline text to the CEO. The CEO issues it precisely as provided. The guideline is not a legislative instrument but is adopted by medical colleges as the professional standard.

Example 2: Emergency interim guideline during a disease outbreak. A novel pathogen emerges that, in the CEO's opinion, must be urgently addressed. The CEO issues interim guidelines without waiting for the Council to develop them (section 14(1)). Within 30 days, the CEO publishes the reasons for urgency and invites public submissions on the issued text. The Council then uses those submissions to develop a definitive guideline through the normal consultation process.

Example 3: Research funding complaint. A researcher's grant application is declined. The researcher believes the assessment panel failed to consider a relevant submission and exercised power without regard to the merits of the particular case. The researcher approaches the CEO first (as required by section 61(1)(e)) and receives an unsatisfactory response. The researcher lodges a complaint with the Commissioner within 12 months on the ground of breach of natural justice (section 58(a)) and the ground of irrelevant consideration (section 58(d)). The Commissioner investigates in private but cannot revisit whether the research deserved funding; the Commissioner can only recommend procedural remedies.

Example 4: Health product company and NHMRC guideline. A company markets a health supplement claiming it reduces risk of a particular disease. The NHMRC has issued guidelines stating there is insufficient evidence to support that claim. The ACCC commences proceedings alleging the company's advertising is misleading. At trial, the NHMRC guideline is used as authoritative evidence of the scientific consensus, consistent with the Court's approach in ACCC v Homeopathy Plus Australia [2014] FCA 1412.

Example 5: Human embryo research licensing. A research institution seeks a licence to conduct research involving excess ART embryos. The licence is assessed by the Embryo Research Licensing Committee of the NHMRC under the Research Involving Human Embryos Act 2002. The Committee is formally a Principal Committee of the NHMRC, but it operates under the Embryos Act framework and outside the complaint jurisdiction of the Commissioner of Complaints under the NHMRC Act.